Kūlike ʻo AI i ka Pae: AI CRO Peptide Collaboration Model Blueprint

Pane wikiwiki

Bridge in silico peptide predictions with physical CRO wet labs through standardized data formats, nā SLA pae, a me nā manaʻo pane QC i pani ʻia.

Kūlike ʻo AI i ka Pae: AI CRO Peptide Collaboration Model Blueprint

Ua hoʻololi maoli ka naʻauao hana hoʻomohala i ka wikiwiki o ka loaʻa ʻana o ka pahuhopu a me ka hoʻolālā molekula i ka ʻepekema ola.. Ua hōʻike ʻia kahi ʻāina koʻikoʻi i kēia hoʻololi ʻana i ka wā i hōʻike ai ʻo Insilico Medicine i kona hiki ke olaola generative ma kāna wahi noiʻi., e hōʻike ana i ka hoʻokumu helu ʻana o ka over 5,000 nā moho peptide hou i loko o kahi pōʻai hoʻolālā 72-hola me ka hoʻohana ʻana i kāna mīkini Biology42. ʻO kēia kūlana hana, heleuma ma ka ʻO Masdar City AI a me ke kikowaena computing quantum, hōʻike i ka hoʻololi hohonu i ka ʻike lāʻau lapaʻau hou: ʻAʻole ʻo ka bottleneck mua i ka wikiwiki o ka algorithm e hiki ai ke hana i nā kaʻina moho, aka, pehea ka hikiwawe o ke kemika kino kino hiki ke synthesize, e hoomaemae, kālailai, a hōʻoia i kēlā mau wānana kikohoʻe.

Kūlike ʻo AI i ka Pae: AI CRO Peptide Collaboration Model Blueprint

Ke hoʻopuka nā kumu hoʻohālike generative i mau tausani o nā moho FASTA sequence a i ʻole SMILES string i nā lā, hui noiʻi kuʻuna kuʻuna (CRO) kū koke nā kumu hoʻohālike kūʻai. Kūlana 3- i ka 5-week synthesis turnaround times e hana i nā backlogs nui, ke hoʻolilo nei i nā paipu hoʻopaʻa helu pipiʻi e noho palaualelo e kali ana i ka ʻikepili paʻa kino. Eia kekahi, hoʻokomo hou i ka ʻikepili manual, mana maikaʻi ʻole (QC) hōʻike, a me nā mea hana kino kikino huna—e like me ke koena ʻakika trifluoroacetic (TFA) cytotoxicity a i ʻole nā ​​helu peptide net - hoʻokomo i ka walaʻau e hoʻohaʻahaʻa i ka hoʻomaʻamaʻa hou ʻana i ke kumu hoʻohālike..

E hopu i ka waiwai piha o ka generative biologics, biopharma R&Pono nā alakaʻi e hoʻokumu i kahi hoʻolaʻa AI CRO peptide kumu hoʻohālike. Hoʻopili kēia ʻano hana i ka ʻokoʻa ma waena o nā wanana silico kiʻekiʻe a me ka hōʻoia ʻana o ka pae kino ma o nā protocol hoʻololi ʻikepili maʻamau., nā SLA hoʻohuli ʻia, a me ka hoʻomalu maikaʻi analytical.

Kūlike ʻo AI i ka Pae: AI CRO Peptide Collaboration Model Blueprint

Ka Generative Bottleneck: Why Computational Output Outpaces Physical Validation

Ke hana nei ka pipeline ʻike lāʻau hou i ka hoʻomau Design-Build-Test-Learn (DBTL) puka manaʻo. I ka loaʻa ʻana o ka liʻiliʻi liʻiliʻi a me ka peptide, ʻO ka māhele "Hoʻolālā" ka palena palena, e koi ana i nā mahina o ka hoʻolālā kemika lāʻau lapaʻau, hoʻopaʻa helu helu, a me ka pilina hana-hana (SAR) palapala palapala.

Ua hoʻohuli ʻo Generative AI i kēia dynamic. Nā hale hoʻonaʻauao hohonu o kēia wā—me nā hiʻohiʻona diffusion, nā kumu hoʻohālike ʻōlelo protein ma muli o ka transformer, a me ka hoʻoikaika ʻana i nā algorithm aʻo - hiki ke loiloi i nā piliona o nā conformers virtual a hoʻopuka i nā tausani o nā kaʻina peptide i hoʻopaʻa ʻia i nā hola. E like me ka mea i hoikeia ma Insilico Medicine's generative biologics benchmark, Hiki i nā ʻenekini helu ke kānana i nā hale waihona puke virtual a hiki i nā moho kūlana kiʻekiʻe e pili ana i ka pilina paʻa i wānana ʻia., hikiwawe, a me ke kūpaʻa metabolic.

Kūlike ʻo AI i ka Pae: AI CRO Peptide Collaboration Model Blueprint

Ki Takeaway: Ua hoʻopaʻa ʻo Generative algorithms i ka māhele "Design" mai nā mahina a i nā hola. No laila, ua neʻe holoʻokoʻa ke kaʻina palena palena i ka ʻike ʻana i ka peptide therapeutic i ka interface "Build-Test" - ʻo ke kino solid-phase peptide synthesis. (SPSS), hoʻomaʻemaʻe wai-phase, a me ka hōʻoia bioanalytical kiʻekiʻe.

Eia naʻe, paʻa mau nā molekala kino e nā kānāwai o ke kemika organik. ʻO ka unuhi ʻana i nā kaʻina kikohoʻe i loko o nā peptides kino mākaukau hoʻāʻo e hoʻolauna i kekahi mau wahi friction koʻikoʻi:

Kūlike ʻo AI i ka Pae: AI CRO Peptide Collaboration Model Blueprint
  1. Hana ʻia a me ka paʻakikī paʻakikī: Hoʻopuka pinepine nā ʻano hoʻohālike AI i nā mea i hoʻopaʻa ʻia, hydrophobic nui loa, a i ʻole nā ​​papa peptide e hana ana i ka pepa beta. Me ka loaʻa ʻole o ka helu ʻana i ka manawa maoli, Ua pilikia kēia mau mea i wānana ʻia mai ka haʻahaʻa haʻahaʻa o ka hui ʻana a me ka hōʻuluʻulu ʻana i ka wā SPPS.

  2. Huli Huli: Inā koi ʻia ka synthesis kino a me ka QC analytical 20 i 30 nā lā ʻoihana, ua haki ka puka manaʻo hoʻomau. ʻAʻole hiki i nā hiʻohiʻona AI ke hoʻomaʻemaʻe i kā lākou mau hana helu me ka ʻole o nā hoʻokomo aʻo ikaika i ka manawa mai nā hoʻokolohua kino.

  3. Hoʻokuʻu ʻia ka ʻikepili: Nā palapala hōʻoia PDF no ka nānā ʻana (CoAs) e koi i nā ʻepekema e kope lima lima i nā wahi maʻemaʻe HPLC a me nā waiwai spectrometry nui i loko o nā ʻikepili helu., ka hoʻolauna ʻana i ka hewa kanaka a me ka pale ʻana i ka hoʻomaʻamaʻa hou ʻana o ka pipeline.


Architectural Pillars of an AI-to-Bench CRO Collaboration Framework

Hoʻokumu i kahi kūpono i loko o ka silico i ka wet lab peptide validation Pono ka pipeline e hoʻololi i nā kahe hana kauoha kūʻai kūʻai aku me kahi hoʻolālā hana hoʻohui. Aia kēia kükohu ma luna o ekolu kia kumu: hoʻololi ʻikepili hiki ke heluhelu ʻia e ka mīkini, nā SLA hoʻohuli ʻia, a me nā palekana QC analytical koʻikoʻi.

Uku Uku Inbound | KA hookeai / MAKEMAKE / Hui JSON v

  • Nā Palekana Pilikino (Hoʻololi TFA-a-Acetate, Maʻiʻo Upena, ʻO ka maʻemaʻe) Uku i waho | CoA hiki ke heluhelu i ka mīkini (JSON/CSV) ʻIkepili Kiʻekiʻe Maka (mzml / Chromatograms) v

MA SILICO GENERATIVE ENGINE (Generative AI / Huli Huli Mea Hana Peptide Lepili / Molecular Scoring) HOOKOLO KINO & PAHU-LAB BENCH

  • Hoʻohui ʻia i ka hana paʻa paʻa (SPSS / Nā ʻĀpana Microplate)

  • ʻO RP-HPLC Māmā & Hooia Nui (HRMS / LC-MS) HOʻOPIʻI LOOP AʻO AʻO HOU (Hoʻoponopono Hoʻohālike Automated & Ka helu ʻana i ka hana pili)

1. Standardized Machine-Readable Data Exchange Schemas

E hoʻopau i ka hoʻokomo ʻikepili manual a hoʻomaʻamaʻa i ka queuing synthesis robotic automated, pono e kamaʻilio ka ʻenekini helu a me ka CRO wet lab ma o ke kūkulu ʻia, nā ukana hiki ke heluhelu ʻia e ka mīkini.

Uku Uku Inbound (Hoʻopuka helu helu → CRO Lab)

Ke koho ka mīkini generative i kahi pūʻulu o nā peptides moho, hoʻokuʻu aku i kahi faila hoʻouna i kūkulu ʻia (JSON a i ʻole CSV) loaʻa i ʻekolu papa ʻikepili koi:

  • ʻIke Kakau & Notation: Hōʻike ʻia nā ʻakika amino kūlohelohe i ka leka IUPAC/IUB helu hoʻokahi; nā ʻakika amino non-canonical, ʻaoʻao-chain cyclizations, a i ʻole nā ​​hoʻololi hope i hōʻike ʻia ma ka Hierarchical Editing Language no Macromolecules (HELM) notation.

  • Kemiformatics Structural: Canonical SMILES a i ʻole SDF hōʻike, e hōʻoia ana i ka mālama ʻana i nā ʻakika d-amino, lipidations, a i ʻole PEG conjugations.

  • Wanaana Kinohi: Ua wānana ʻia ke kiko isoelectric (pI), helu helu hydrophobicity, a me ka paepae maʻemaʻe pahuhopu (e.g., ka nānā ʻana i ke kino vs. ≥95% hoʻomaʻemaʻe alakaʻi optimization).

Uku i waho (CRO Lab → Pipeline Aʻo Aʻe)

Oligopeptides 41 I ka pau ʻana o ka synthesis kino a me ka hoʻāʻo analytical, hoʻokuʻu aku ka CRO i nā pūʻolo QC i kūkulu ʻia i ka loko ʻikepili kapua o ka mea kūʻai aku a i ʻole LIMS ma o API:

  • CoA hiki ke heluhelu i ka mīkini (JSON/CSV): Loaʻa i ka pūʻulu ID, helu ʻia ka nui monoisotopic, ʻike ʻia ka ratio mass-to-charge (m/z), RP-HPLC wahi kiʻekiʻe maʻemaʻe pakeneka, pākēneka maʻiʻo peptide net, ʻike paʻakai koena, a me nā pae endotoxin.

  • Nā waihona kikoo maka: ʻikepili maka hiki ke heluhelu ʻia e ka mīkini, me nā faila format mzML no ka spectrometry nuipa a me ASCII/CSV maka chromatographic meheu no HPLC.

2. Tiered SLA Benchmarks for High-Throughput Peptide Synthesis

Pono nā pae like ʻole o ka ʻike ʻana i ka lāʻau i nā kaulike like ʻole o ka wikiwiki, ka maemae, a me ka nui. Ke hoʻokau nei i kahi ʻaʻahu ≥98% koi maʻemaʻe ma ka nānā mua ʻana Hale Hana Mea Hana Peptide hoʻopau nā arrays i ka manawa a me ke kālā. ʻO ka ʻokoʻa, ʻO ka hoʻohana ʻana i nā peptides crude i nā hoʻāʻo e pili ana i ke kelepona e hoʻopilikia i nā helu hoʻopunipuni maikaʻi ʻole a maikaʻi ʻole ma muli o ka pau ʻana o nā haumia..

Acetyl Hexapeptide 38 ʻO kahi i hoʻopaʻa ʻia kiʻekiʻe-throughput peptide synthesis SLA E holo ana ka framework ma waena o ʻekolu papa hana ʻokoʻa:

HAAWINA 3: PRECLINICAL SCALEUP 100mg - Grams | >98% Maemae | 15-20 BD SLA na moho alakai TIER 2: KA OPTIMIZATION LEAD 5mg – 25mg | >95% Maemae | 10-12 BD SLA i ike ia na Hits TIER 1: NĀ HOʻOPIʻI HIGH-THROUGHPUT 1mg – 5mg | >85% / ʻAʻole | 5-7 BD SLA

ʻĀpana 1: Nā Hōʻike Hōʻikeʻike Kiʻekiʻe (DBTL holo wikiwiki)

  • Kaulike: 1 mg i 5 mg i kēlā me kēia kaʻina i nā format array 96-well a i ʻole 384-well.

  • Pahu Hoomaemae: Crude i >85% ka maemae.

  • Hoʻololi SLA: 5 i 7 nā lā ʻoihana.

  • Hoʻohana mua: Ka nānā ʻana i ka pilina pili mua me ka Surface Plasmon Resonance (SPR), Bio-Layer Interferometry (LILO), a i ʻole Fluorescence Polarization (FP). E kānana wikiwiki i nā tausani o nā wānana AI a hiki i nā mea paʻa kiʻekiʻe.

ʻĀpana 2: Hoʻonui alakaʻi & Paʻi Re-Synthesis

  • Kaulike: 5 mg i 25 mg.

  • Pahu Hoomaemae: ≥95% maʻemaʻe i hōʻoia ʻia ma o ka Reverse-Phase HPLC.

  • Hoʻololi SLA: 10 i 12 nā lā ʻoihana.

  • Hoʻohana mua: Nā bioassays hana lua (EC50/IC50 hoʻoholo), hoʻāʻo paʻa plasma, a me ka hoʻomaʻemaʻe metabolic assays.

ʻĀpana 3: ʻO ka hoʻonui ʻana i ka preclinical & Hoʻololi

  • Kaulike: 100 mg i ka nui-gram nui.

  • Pahu Hoomaemae: ≥98% maʻemaʻe i hōʻoia ʻia me ka hoʻololi kūʻē kūʻē piha.

  • Hoʻololi SLA: 15 i 20 nā lā ʻoihana.

  • Hoʻohana mua: In vivo pharmacokinetics (PK/PD), toxicology holoholona, a me nā haʻawina preclinical e hiki ai iā IND.

No ke kōkua: Ke kūkākūkā nei i nā ʻaelike CRO no nā papahana AI generative, E hoʻokumu i nā SLA hoʻololi i hoʻopaʻa ʻia i hoʻopaʻa ʻia i ka synthesis array automated ma mua o nā kauoha hoʻokahi.. Ka launa pū me nā mea hoʻolako kūikawā like MOL Changes, e hoʻohana ana i nā paepae hoʻoheheʻe paʻa paʻa i loko o ka Papa 100 kaiapuni lumi maemae, hōʻoia i ka hoʻokō wikiwiki ʻana me ka ʻole o ka hoʻopaʻapaʻa ʻana i ka paʻa ʻana o ka hui.


3. QC hōʻike & Nā Palekana Pilikino

I ka ʻike lāʻau algorithmic, he pōʻino ka ʻikepili hoʻokolohua walaʻau a pololei ʻole: hoʻomaʻamaʻa hou ia i nā hiʻohiʻona generative ma nā kuhi hewa, skewing wānana moho e hiki mai ana. No ka hōʻoia ʻana i nā mea hoʻokomo aʻo ikaika kiʻekiʻe, Pono ka hōʻoia CRO kino e hoʻokō i ʻehā mau kikoʻī loiloi koʻikoʻi.

Mass & Hōʻoia ʻIke (HRMS / LC-MS/MS)

Pono kēlā me kēia pūʻulu synthesized e komo i ka spectrometry lehulehu (ESI-TOF a i ʻole MALDI-TOF) e hōʻoia i ka paona molekala monoisotopic e kūʻē i nā hana molekala i wānana ʻia. No nā kaʻina paʻakikī i loaʻa nā alahaka disulfide a i ʻole isobaric amino acids, tandem LC-MS/MS fragment analysis hōʻoia i ka pili pono a me ka hoʻonohonoho ʻana.

Helu Maemae (RP-HPLC)

Pono e loiloi ʻia ka maʻemaʻe me ka hoʻohana ʻana i ka Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) me nā kolamu silica C18 a i ʻole C4 maikaʻi a me ka waikawa trifluoroacetic (TFA) / acetonitrile gradients. Hoʻohui o ka ultraviolet (UV) hoʻopaʻa ʻana ma 214 nm a 254 hōʻoia ʻo nm i ka ʻike pololei ʻana o ka peptide backbone absorption a me nā kaulahao ʻaoʻao ʻala.

TFA-a-Acetate Counterion Exchange

Hoʻohana ka solid-phase peptide synthesis i ka TFA i ka wā o ka cleavage resin a me ka hoʻomaʻemaʻe HPLC. Ma ka hopena, Hāʻawi maoli ʻia nā peptides maʻamau e like me nā paʻakai trifluoroacetate.

Eia naʻe, ʻO ke koena TFA ka ikaika e kū'ē i nā pūnaewele ola: ʻO nā haʻahaʻa TFA e like me ka haʻahaʻa 0.01% hiki ke hoʻoulu i ka hoʻopau ʻana o ka membrane cell a me ka make cell i nā hoʻokolohua hana, e alakaʻi ana i ka heluhelu ʻana i nā ʻawaʻawa maikaʻi wahaheʻe.

⚠️ ʻŌlelo Aʻo: Mai hoʻokomo pololei i nā peptides TFA-paʻakai maka i loko o nā hoʻāʻo hana ma ke kelepona. No nā pae āpau 2 a me Tier 3 nā haʻawina hōʻoia, e hoʻokō i ka hoʻololi kū'ē kū'ē mai ka trifluoroacetate i ka acetate a i ʻole nā ​​paʻakai chloride e pale ai i nā mea hana kino-cell..

ʻO ka hoʻoholo ʻana i ka maʻiʻo Peptide Net

ʻAʻole ʻo Lyophilized peptide pauka 100% pūmua peptide maʻemaʻe. Loaʻa nā counterions paʻa, ʻimi i nā mea hoʻoheheʻe organik, a hoʻopaʻa i ka wai. ʻO ka mea maoli maʻiʻo peptide net maʻamau ma waena 65% a 85% o ke kaumaha maloo a pau.

Inā koi ʻia kahi protocol assay no ka hoʻomākaukau ʻana i kahi 10 mM hoʻonā waiwai i hoʻokumu wale ʻia ma ke kaumaha maloʻo, e hoʻohaʻahaʻa ʻia ka manaʻo peptide maoli e 15% i 35%. Hoʻololi kēia kuhi kuhi hewa i nā kinetics paʻa i helu ʻia (Kd) a me ka mana hana (EC50). Pono nā pūʻolo CRO e kākoʻo ana i ka hōʻoia ʻana o AI e hōʻike i ka ʻike kikoʻī peptide net i hoʻoholo ʻia ma o ka hoʻopaʻa ʻana i ka nitrogen elemental (CHN) a i ʻole ka nānā ʻana i ka waikawa amino (AAA).


Operationalizing Hoʻopaʻa-Loop Model Retraining

ʻO ka pahuhopu hope loa o a ʻike ʻia ka peptide DBTL loop pani he aʻo ikaika ka framework: ka hoʻohana ʻana i nā hopena hoʻokolohua kino e hoʻomau mau i nā algorithms helu helu generative.

v

  • Hoʻoponopono i nā ʻano hoʻopaʻa kinetic mau (Kd) e pili ana i ka paona peptide net maoli v

PHYSICAL WET-LAB QC DATA HOPU

  • HRMS Monoisotopic Mass Verification

  • RP-HPLC Chromatographic Purity Profile

  • Ana hoʻonā & Maʻiʻo Peptide Net % HOOPONOPONO HAPA AUMI & HOOLAHA

  • Exclude false negatives caused by residual TFA cytotoxicity AI MODEL RETRAINING & HI'O PAUNA HOU

  • Hoʻohou i nā hana hoʻopaʻa helu ʻana

  • E hoʻomaʻemaʻe i nā ʻāina ikehu kaʻina-a-solubility

When physical CRO data flows back into the computational pipeline, automated error-checking scripts must evaluate the dataset before model retraining occurs: Kūʻai mākou 290

  1. Hiki i ka Synthetic ke kaupaona hou: Inā nā motif kaʻina kikoʻī (e.g., ʻO nā trimers hydrophobic hou a i ʻole poly-glutamine kikoo) hāʻule mau i ka synthesis a i ʻole ka hua <10% ka maemae ole, the AI model automatically increases the penalty score for those synthetic patterns in future design cycles.

  2. Ka hoʻoheheʻe & Hoʻohui Hoʻohui: Physical solubility metrics observed during reconstitution are mapped against predicted lipophilicity parameters (LogP/LogD), refining the AI’s biophysical property prediction models.

  3. Hoʻoponopono hoʻohālikelike: Kinetic constants derived from SPR/BLI are automatically scaled using measured net peptide content values, ensuring that affinity scoring models train on exact molecular concentrations.

ʻO ka hōʻailona hopena o ka hana: ʻO ka hoʻololi ʻana mai nā kauoha CRO transactional kuʻuna i kahi hoʻolālā DBTL paʻa paʻa i hoʻohui ʻia e loaʻa i nā loaʻa hana ma waena o biopharma R&D nā paipu:

  • 50% Hoemi i ka DBTL Cycle Time: Rapid automated array synthesis slashes physical validation turnaround from 4 nā pule ma lalo o 5-7 mau lā ʻoihana.

  • 60% Hoʻonui ʻia i ka Hoʻoikaika Aʻo ʻana: Automated machine-readable QC ingestion eliminates manual data re-entry bottlenecks and human transcription errors.

  • 35% ʻOi aku ka pololei o ke kŘkohu helu kiʻekiʻe: ʻO ka hoʻomaʻamaʻa maʻamau i ka ʻikepili paʻa e pili ana i ka ʻikepili peptide net maoli a me ka wehe ʻana i ka leo cytotoxicity TFA e hoʻomaikaʻi nui i nā wānana pili pili..


SLA hana & QC Benchmark Matrix no nā papahana AI Peptide

E alakaʻi i ke kūʻai a me R&D ka hoʻoholo ʻana, Hōʻike ka matrix aʻe i nā kikoʻī hana maʻamau ma nā pae mua o kahi papahana ʻike peptide i alakaʻi ʻia e AI.:

Pae ʻIke

Laulā unahi

Pahu hoʻomaʻemaʻe liʻiliʻi

Hoʻololi SLA

Pāke QC Pono

Noi Bioassay kumu mua

ʻĀpana 1: Nā ʻĀpana Nānā

1 mg – 5 mg

Crude i >85%

5–7 La Hana Hana

ʻIkepili LC-MS, Huli RP-HPLC, Palapala Palapala JSON

Nā Papa Hoʻopaʻa Kiʻekiʻe (SPR, LILO, FP)

ʻĀpana 2: Hoʻonui alakaʻi

5 mg – 25 mg

≥95% i hōʻoia ʻia

10-12 mau lā ʻoihana

HRMS, RP-HPLC UV214/254, Maʻiʻo Peptide Net %

Nā ho'āʻo hana ma muli o ke kelepona lua (EC_{50}/IC_{50})

ʻĀpana 3: ʻO ka hoʻonui ʻana i ka preclinical

100 mg – Nui-Gram

≥98% i hōʻoia ʻia

15-20 mau lā ʻoihana

HRMS, RP-HPLC, Hoʻololi TFA-a-Acetate, LAL Endotoxin (<0.1 EU/mg)

Ma Vivo PK/PD, Hoʻonaʻauao kino, Hōʻoia Preclinical IND


ʻO ke alanui hoʻokō hoʻolālā no Biopharma R&D Na alakai

Ke kūkulu ʻana i kahi agile, Pono ʻo AI-ready CRO collaboration infrastructure i ka hoʻonohonoho ʻōnaehana ma waena o ka helu helu, wet-lab, a me nā hui kūʻai. ʻO Biopharma R&Pono nā alakaʻi e hoʻokō i kahi palapala alanui hoʻokō ʻekolu mau ʻanuʻu:

  1. Hoʻohālikelike i nā Interface Ingestion: E hoʻololi i nā paepae helu i loko mai ka hoʻokuʻu ʻana aku i nā pāpaʻi paʻa i ka hana ʻana i nā uku uku JSON/HELM. E hoʻokumu i nā kiko kikoʻī API kapua no ka loaʻa ʻana o nā pūʻolo analytical CRO hiki ke heluhelu ʻia e ka mīkini.

  2. E hoʻokumu i nā SLA Kūʻai Kūʻai: E neʻe aku mai ka ʻoʻoleʻa, ʻaelike kūʻai maʻemaʻe hoʻokahi. Nā ʻaelike lawelawe haku hale (MSA) e hoʻokomo i ka Tier 1 ʻO nā koho hoʻololi wikiwiki 5 lā no ka nānā mua ʻana.

  3. Hoahana me nā CRO Kūikawā Kūikawā Kiʻekiʻe: E koho i nā hoa hana synthesis i hoʻolako ʻia me nā mea kani SPPS hou, Papa 100 kaiapuni hana sterile, a me nā waihona hoʻololi ikaika (e.g., cyclization, nā ʻakika amino kūlohelohe, hoʻopili ʻana i ka lipid).

Ma ka hoʻololi ʻana i nā kahe hana lima i hoʻokaʻawale ʻia me kahi hoʻolālā ʻikepili pani pani a me ka hoʻokō kino pono., Hiki i nā hui biopharma ke hoʻomaopopo piha i ka ʻōlelo hoʻohiki o ka generative AI-e hoʻohuli i nā wānana kaʻina kikohoʻe i mau moho lāʻau lapaʻau i hoʻopaʻa ʻia i ka wikiwiki ʻole..


No ka mea kakau

Ua haku ʻia kēia ʻano e ka Hoʻololi ʻo MOL i ka Peptide R&Hui D, he hui kūikawā o nā lāʻau lapaʻau, nā ʻenekini hana bioprocess, a me nā kānaka ʻepekema bioanalytical i hoʻolaʻa i ka holomua ʻana i ka maʻemaʻe kiʻekiʻe, ʻO ka peptide synthesis automated a me ka hana sterile no ka noiʻi biopharma ʻokiʻoki.


Nā ʻanuʻu aʻe no kāu Pipeline Discovery Peptide

Ka loiloi ʻana i nā hoa hana synthesis maʻamau e kākoʻo i kāu mau kahe hana ʻike i alakaʻi ʻia e AI? E ʻimi ʻO ka MOL Changes 'kūlana peptide synthesis platform e aʻo pehea kā mākou Papa 100 lumi hoʻomaʻemaʻe, 300+ nā mana hoʻololi hana, a hiki i nā SLA huli wikiwiki ke hoʻoikaika i kāu hōʻoia moho. ʻO Caprooyl Tetrapeptide 3

Bingyan Gao

Bingyan Gao

Mea Hana Pono a me Analytical Kaʻike kumu: ʻO ka hoʻokaʻawale ʻana a me ka ʻike ʻana i nā ʻano haumia, Hoʻomohala ʻano hana HPLC/MS, ka hoʻomaʻemaʻe kiral, a me ka hoʻokō ʻana i nā pharmacopoeias honua.

Pilikino: ʻO Bingyan Gao ka "puka kiaʻi hope" o ka maʻemaʻe peptide a me ka maikaʻi. Maikaʻi ʻo ia i ka hoʻohana ʻana i nā mea analytical kiʻekiʻe kiʻekiʻe a loea i ka hoʻomohala ʻana i nā ʻano hoʻokaʻawale chromatographic maʻamau no nā peptides hoʻololi paʻakikī.. Ua hoʻokumu ʻo ia i kahi ʻōnaehana hoʻomaʻemaʻe pono ʻole e hōʻoia i ka maʻemaʻe o ka huahana 99% a i ʻole kiʻekiʻe aʻe akā ʻike pono a hoʻopau i nā ʻano haumia i hiki ke hoʻoulu i ka immunogenicity. Me ka hoʻomaopopo hohonu ʻana i nā koi hoʻoponopono FDA a me EMA no nā lāʻau peptide, hōʻoia ʻo ia ʻo kēlā me kēia pūʻulu i hoʻokuʻu ʻia mai ka hale hana e hele pū ʻia me kahi palapala hōʻoia o ka ʻike ʻana (COA).

ʻIke ʻia & Nā alakaʻi hoʻoponopono
Nānā ʻia e: Ka poe akamai kumuhana
Kaʻana like i kēia ʻatikala
Home Huli Whatsapp Nā lawelawe Huahana